Free Trial
→ Collect $1,170 a month from silver (From Investors Alley) (Ad)tc pixel Free JAZZ Stock Alerts

Jazz Pharmaceuticals (JAZZ) Financials

Jazz Pharmaceuticals logo
$230.06 -2.27 (-0.98%)
As of 02:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Jazz Pharmaceuticals

Annual Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 330 397 488 447 523 239 -330 -224 415 560 -356
Consolidated Net Income / (Loss)		 330 397 488 447 523 239 -330 -224 415 560 -356
Net Income / (Loss) Continuing Operations		 330 397 488 447 523 239 -330 -224 415 560 -356
Total Pre-Tax Income 		436 532 441 529 454 275 -113 -373 298 470 -628
Total Operating Income		 508 592 529 615 532 378 170 -66 579 717 -430
Total Gross Profit		 1,222 1,383 1,509 1,769 2,034 2,215 2,653 3,119 3,399 3,623 3,764
Total Revenue		 1,325 1,488 1,619 1,891 2,162 2,364 3,094 3,659 3,834 4,069 4,268
Operating Revenue		 1,325 1,488 1,619 1,891 2,162 2,364 3,094 3,659 3,834 4,069 4,268
Total Cost of Revenue		 103 105 110 122 128 149 441 541 436 446 503
Operating Cost of Revenue		 103 105 110 122 128 149 441 541 436 446 503
Total Operating Expenses		 714 791 980 1,155 1,501 1,837 2,483 3,184 2,820 2,907 4,195
Selling, General & Admin Expense		 449 503 544 684 737 854 1,452 1,417 1,343 1,385 1,809
Research & Development Expense		 135 186 283 227 410 587 506 1,035 869 894 1,731
Amortization Expense		 98 102 152 201 355 260 526 599 608 627 655
Total Other Income / (Expense), net		 -72 -59 -88 -85 -78 -103 -283 -307 -281 -246 -198
Interest & Investment Income		 -57 -62 -78 -79 -72 -100 -279 -288 -289 -238 -195
Other Income / (Expense), net		 1.45 3.37 -9.97 -6.88 -5.81 -3.27 -4.35 -19 8.79 -8.18 -2.57
Income Tax Expense		 106 135 -48 80 -73 34 216 -159 -120 -91 -272
Other Gains / (Losses), net		 0.00 -0.38 -1.01 -2.20 -4.09 -2.96 -0.71 -9.92 -3.01 -1.66 -0.73
Basic Earnings per Share		 $5.38 $6.56 $8.13 $7.45 $9.22 $4.28 ($5.52) ($3.58) $6.55 $9.06 ($5.84)
Weighted Average Basic Shares Outstanding		 61.23M 60.50M 60.02M 59.98M 56.75M 55.71M 59.69M 62.54M 63.29M 61.84M 60.98M
Diluted Earnings per Share		 $5.23 $6.41 $7.96 $7.30 $9.09 $4.22 ($5.52) ($3.58) $6.10 $8.65 ($5.84)
Weighted Average Diluted Shares Outstanding		 63.04M 61.87M 61.32M 61.22M 57.55M 56.52M 59.69M 62.54M 72.07M 66.01M 60.98M
Weighted Average Basic & Diluted Shares Outstanding		 61.30M 60.50M 60M 60M 56.13M 56.33M 61.74M 63.33M 62.35M 60.73M 61.56M

Quarterly Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 147 94 -15 169 215 191 -93 -718 251 203 293
Consolidated Net Income / (Loss)		 147 94 -15 169 215 191 -93 -718 251 203 293
Net Income / (Loss) Continuing Operations		 147 94 -15 169 215 191 -93 -718 251 203 293
Total Pre-Tax Income 		100 62 -1.60 138 201 133 -110 -736 9.04 208 299
Total Operating Income		 172 122 66 199 260 191 -56 -686 58 255 337
Total Gross Profit		 870 905 806 914 943 959 793 929 997 1,044 935
Total Revenue		 972 1,012 902 1,024 1,055 1,088 898 1,046 1,126 1,198 1,069
Operating Revenue		 972 1,012 902 1,024 1,055 1,088 898 1,046 1,126 1,198 1,069
Total Cost of Revenue		 102 107 95 110 112 129 105 116 129 154 134
Operating Cost of Revenue		 102 107 95 110 112 129 105 116 129 154 134
Total Operating Expenses		 698 782 740 714 683 769 849 1,616 940 790 598
Selling, General & Admin Expense		 308 396 352 339 326 369 514 358 531 406 353
Research & Development Expense		 234 235 233 221 200 241 181 1,095 241 214 196
Amortization Expense		 155 152 156 155 157 159 154 162 168 170 172
Other Special Charges / (Income)		 - - - - - - 0.00 - - - -123
Total Other Income / (Expense), net		 -73 -61 -68 -62 -59 -58 -54 -49 -48 -46 -37
Interest & Investment Income		 -71 -70 -66 -62 -59 -51 -54 -47 -49 -45 -40
Other Income / (Expense), net		 -1.38 9.35 -1.69 0.51 -0.70 -6.30 -0.20 -1.80 0.10 -0.66 2.50
Income Tax Expense		 -47 -33 12 -31 -15 -58 -18 -17 -242 4.96 6.10
Other Gains / (Losses), net		 0.13 -0.46 -1.35 -0.01 -0.29 -0.02 -0.50 -0.09 -0.05 -0.06 0.00
Basic Earnings per Share		 $2.33 $1.50 ($0.23) $2.68 $3.50 $3.11 ($1.52) ($11.74) $4.14 $3.28 $4.73
Weighted Average Basic Shares Outstanding		 63.11M 63.29M 62.54M 62.88M 61.41M 61.84M 61M 61.19M 60.70M 60.98M 61.90M
Diluted Earnings per Share		 $2.14 $1.40 ($0.23) $2.49 $3.42 $2.97 ($1.52) ($11.74) $4.08 $3.34 $4.43
Weighted Average Diluted Shares Outstanding		 71.29M 72.07M 62.54M 69.63M 63.17M 66.01M 61M 61.19M 61.61M 60.98M 66.10M
Weighted Average Basic & Diluted Shares Outstanding		 62.96M 62.35M 63.04M 61.75M 60.45M 60.73M 61.63M 60.66M 60.77M 61.56M 62.74M

Annual Cash Flow Statements for Jazz Pharmaceuticals

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 305 -623 20 -75 328 420 -466 290 625 907 -1,021
Net Cash From Operating Activities		 532 592 693 799 776 900 779 1,272 1,092 1,396 1,356
Net Cash From Continuing Operating Activities		 532 592 693 799 776 900 779 1,272 1,092 1,396 1,356
Net Income / (Loss) Continuing Operations		 330 397 488 447 523 239 -330 -224 415 560 -356
Consolidated Net Income / (Loss)		 330 397 488 447 523 239 -330 -224 415 560 -356
Depreciation Expense		 9.89 12 13 15 15 19 27 30 30 33 42
Amortization Expense		 121 124 182 245 355 260 526 599 608 627 655
Non-Cash Adjustments To Reconcile Net Income		 139 122 209 159 288 618 550 1,164 503 461 1,442
Changes in Operating Assets and Liabilities, net		 -67 -62 -199 -68 -405 -235 5.66 -297 -465 -285 -426
Net Cash From Investing Activities		 -2.26 -1,751 -269 -394 -155 -1,008 -5,212 -446 -163 -508 -1,510
Net Cash From Continuing Investing Activities		 -2.26 -1,751 -269 -394 -155 -1,008 -5,212 -446 -163 -508 -1,510
Purchase of Property, Plant & Equipment		 -36 -9.69 -29 -20 -40 -15 -28 -29 -24 -38 -917
Acquisitions		 0.00 -1,676 -85 -111 -197 -364 -6,253 -469 -19 -10 -151
Purchase of Investments		 0.00 -132 -385 -1,166 -917 -2,398 -27 -61 -390 -1,305 -1,830
Sale of Property, Plant & Equipment		 - 0.00 0.00 48 14 - - - 0.00 0.00 28
Sale and/or Maturity of Investments		 0.00 67 230 855 985 1,755 1,095 60 270 845 1,360
Net Cash From Financing Activities		 -214 541 -409 -479 -294 528 3,971 -529 -305 21 -873
Net Cash From Continuing Financing Activities		 -214 541 -409 -479 -294 528 3,971 -529 -305 21 -873
Repayment of Debt		 -1,066 -178 -886 -32 -33 -890 -1,321 -582 -31 -612 -781
Repurchase of Common Equity		 -62 -278 -99 -524 -301 -147 0.00 -0.05 -270 -311 -125
Issuance of Debt		 899 995 559 0.00 0.00 1,481 5,191 0.00 0.00 981 0.00
Issuance of Common Equity		 41 24 32 93 58 100 135 98 46 21 108
Other Financing Activities, net		 -26 -21 -15 -17 -17 -17 -36 -45 -51 -58 -75
Other Net Changes in Cash		 - - 5.05 - - - -3.21 -6.22 1.14 - 6.56
Cash Interest Paid		 40 40 45 43 43 42 138 271 333 315 249
Cash Income Taxes Paid		 146 160 174 164 184 227 271 95 178 115 122

Quarterly Cash Flow Statements for Jazz Pharmaceuticals

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 53 171 -63 -88 862 195 -551 -672 136 66 452
Net Cash From Operating Activities		 307 167 267 331 399 399 430 89 475 363 408
Net Cash From Continuing Operating Activities		 307 167 267 331 399 399 430 89 475 363 408
Net Income / (Loss) Continuing Operations		 147 94 -15 169 215 191 -93 -718 251 203 293
Consolidated Net Income / (Loss)		 147 94 -15 169 215 191 -93 -718 251 203 293
Depreciation Expense		 7.68 7.65 7.65 7.81 7.78 9.51 10 12 9.88 9.43 9.10
Amortization Expense		 155 152 156 155 157 159 154 162 168 170 172
Non-Cash Adjustments To Reconcile Net Income		 104 131 132 105 113 128 114 1,033 189 100 12
Changes in Operating Assets and Liabilities, net		 -106 -217 -14 -105 -94 -89 244 -400 -144 -120 -78
Net Cash From Investing Activities		 -174 102 -272 -257 214 -193 -169 -641 -328 -372 123
Net Cash From Continuing Investing Activities		 -174 102 -272 -257 214 -193 -169 -641 -328 -372 123
Purchase of Property, Plant & Equipment		 -4.30 -10 -6.90 -7.09 -11 -13 -14 -871 -15 -17 -97
Acquisitions		 - -18 -10 - - - -25 - -73 -54 0.00
Purchase of Investments		 -190 -120 -375 -330 -130 -470 -440 -240 -640 -510 -500
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 200
Sale and/or Maturity of Investments		 20 250 120 80 355 290 310 470 400 180 520
Net Cash From Financing Activities		 -78 -100 -57 -161 246 -8.28 -814 -125 -11 75 -79
Net Cash From Continuing Financing Activities		 -78 -100 -57 -161 246 -8.28 -814 -125 -11 75 -79
Repayment of Debt		 -7.75 -7.75 -7.75 -7.75 -583 -13 -758 -7.75 -7.75 -7.75 -7.80
Issuance of Common Equity		 5.51 8.85 0.49 11 0.02 9.20 12 10 0.73 85 33
Other Financing Activities, net		 -1.88 -1.61 -49 -2.85 -1.61 -4.01 -67 -2.25 -3.81 -2.00 -104
Effect of Exchange Rate Changes		 - - - - - - - - - - -0.40

Annual Balance Sheets for Jazz Pharmaceuticals

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3,333 4,800 5,124 5,203 5,539 6,536 12,299 10,835 11,393 12,012 11,659
Total Current Assets		 1,258 748 968 1,234 1,630 2,840 2,611 2,606 3,435 4,629 4,166
Cash & Equivalents		 989 366 386 310 637 1,058 591 881 1,506 2,413 1,392
Short-Term Investments		 0.00 60 215 515 440 1,075 - 0.00 120 580 1,050
Accounts Receivable		 210 234 224 264 356 396 563 651 706 717 831
Inventories, net		 19 34 43 53 79 95 1,073 714 597 480 417
Prepaid Expenses		 21 25 23 25 39 62 131 92 185 177 153
Other Current Assets		 19 29 77 68 79 152 252 267 321 262 324
Plant, Property, & Equipment, net		 86 107 170 200 132 128 257 228 170 173 200
Total Noncurrent Assets		 1,989 3,945 3,985 3,769 3,777 3,568 9,430 8,001 7,788 7,210 7,293
Goodwill		 657 894 948 928 920 958 1,828 1,693 1,753 1,716 1,829
Intangible Assets		 1,186 3,012 2,979 2,731 2,441 2,195 7,152 5,794 5,418 4,756 4,430
Noncurrent Deferred & Refundable Income Taxes		 130 15 35 58 221 255 311 376 478 560 869
Other Noncurrent Operating Assets		 9.27 14 16 43 187 155 127 128 133 168 158
Other Noncurrent Nonoperating Assets		 7.21 9.74 7.67 9.59 7.43 5.24 12 9.25 6.48 9.49 7.60
Total Liabilities & Shareholders' Equity		 3,333 4,800 5,124 5,203 5,539 6,536 12,299 10,835 11,393 12,012 11,659
Total Liabilities		 1,734 2,923 2,411 2,446 2,428 2,876 8,333 7,750 7,656 7,919 7,341
Total Current Liabilities		 227 257 294 345 364 654 809 933 1,537 1,039 2,243
Short-Term Debt		 38 36 41 33 33 246 31 31 605 31 1,030
Accounts Payable		 22 22 24 41 46 27 100 91 103 78 122
Accrued Expenses		 164 193 199 265 270 353 666 803 794 911 1,034
Current Deferred & Payable Income Tax Liabilities		 1.81 4.51 22 1.20 11 25 9.61 7.72 35 19 56
Total Noncurrent Liabilities		 1,507 2,665 2,117 2,101 2,063 2,222 7,524 6,816 6,120 6,880 5,098
Long-Term Debt		 1,151 1,994 1,540 1,563 1,574 1,849 6,019 5,693 5,108 6,078 4,328
Noncurrent Deferred & Payable Income Tax Liabilities		 283 557 383 309 224 130 1,301 944 848 677 595
Other Noncurrent Operating Liabilities		 69 113 177 219 261 241 204 179 164 126 175
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,599 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Total Preferred & Common Equity		 1,599 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Total Common Equity		 1,599 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Common Stock		 1,563 1,665 1,935 2,114 2,266 2,634 3,535 3,477 3,700 3,914 4,241
Retained Earnings		 303 529 918 841 1,068 1,160 830 734 879 1,127 646
Accumulated Other Comprehensive Income / (Loss)		 -267 -317 -141 -198 -223 -134 -400 -1,126 -842 -948 -569
Other Equity Adjustments		 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.60

Quarterly Balance Sheets for Jazz Pharmaceuticals

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 10,385 11,047 11,261 11,204 11,327 11,362 12,256 11,535 10,944 11,356 11,860
Total Current Assets		 2,572 2,785 3,010 3,246 3,540 3,682 4,390 4,128 3,350 3,756 4,583
Cash & Equivalents		 839 1,168 1,282 1,336 1,443 1,356 2,218 1,862 1,190 1,326 1,844
Short-Term Investments		 60 - 80 250 375 625 400 710 480 720 1,030
Accounts Receivable		 601 624 610 628 707 698 724 653 714 764 836
Inventories, net		 728 675 657 612 577 543 539 493 505 483 438
Prepaid Expenses		 93 73 107 110 123 134 155 150 164 147 150
Other Current Assets		 250 245 272 310 315 326 354 260 298 315 285
Plant, Property, & Equipment, net		 216 228 229 222 166 169 176 179 185 189 203
Total Noncurrent Assets		 7,597 8,035 8,021 7,736 7,621 7,511 7,689 7,228 7,409 7,412 7,073
Goodwill		 1,593 1,723 1,743 1,705 1,739 1,736 1,805 1,760 1,844 1,827 1,805
Intangible Assets		 5,570 5,764 5,706 5,418 5,235 5,079 5,144 4,718 4,769 4,566 4,204
Noncurrent Deferred & Refundable Income Taxes		 315 399 430 464 508 545 583 575 603 846 907
Other Noncurrent Operating Assets		 109 140 135 141 132 145 152 166 184 164 151
Other Noncurrent Nonoperating Assets		 9.95 8.56 7.87 7.17 5.78 5.74 4.40 9.00 8.52 8.03 7.10
Total Liabilities & Shareholders' Equity		 10,385 11,047 11,261 11,204 11,327 11,362 12,256 11,535 10,944 11,356 11,860
Total Liabilities		 7,639 7,712 7,735 7,715 7,631 7,599 8,085 7,360 7,238 7,397 7,327
Total Current Liabilities		 813 909 945 1,573 1,562 1,556 1,030 1,223 2,071 2,274 2,247
Short-Term Debt		 31 31 31 605 605 606 31 31 1,028 1,029 1,031
Accounts Payable		 102 125 98 110 81 97 85 96 89 152 100
Accrued Expenses		 668 712 748 770 827 801 859 1,064 875 1,002 1,022
Current Deferred & Payable Income Tax Liabilities		 10 40 68 89 49 52 55 32 79 91 94
Total Noncurrent Liabilities		 6,827 6,803 6,790 6,141 6,068 6,043 7,055 6,137 5,167 5,123 5,081
Long-Term Debt		 5,696 5,690 5,687 5,111 5,105 5,101 6,081 5,336 4,336 4,332 4,324
Noncurrent Deferred & Payable Income Tax Liabilities		 934 932 911 841 810 775 792 671 682 629 548
Other Noncurrent Operating Liabilities		 197 181 192 189 154 167 182 130 149 162 209
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,745 3,335 3,526 3,489 3,696 3,763 4,171 4,175 3,706 3,959 4,532
Total Preferred & Common Equity		 2,745 3,335 3,526 3,489 3,696 3,763 4,171 4,175 3,706 3,959 4,532
Total Common Equity		 2,745 3,335 3,526 3,489 3,696 3,763 4,171 4,175 3,706 3,959 4,532
Common Stock		 3,388 3,512 3,580 3,640 3,714 3,779 3,838 3,925 4,000 4,086 4,244
Retained Earnings		 974 803 812 884 864 871 936 1,035 191 443 939
Accumulated Other Comprehensive Income / (Loss)		 -1,618 -980 -867 -1,035 -882 -888 -603 -786 -486 -570 -651
Other Equity Adjustments		 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.60

Annual Metrics And Ratios for Jazz Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.95% 12.32% 8.79% 16.82% 14.32% 9.34% 30.91% 18.26% 4.78% 6.12% 4.88%
EBITDA Growth		 82.12% 14.13% -2.31% 21.65% 3.23% -27.17% 10.01% -24.15% 125.00% 11.62% -80.75%
EBIT Growth		 149.51% 16.75% -12.80% 17.17% -13.39% -28.82% -55.73% -150.95% 794.76% 20.61% -161.09%
NOPAT Growth		 419.30% 14.89% 32.78% -10.98% 18.47% -46.29% -64.10% -138.48% 1,869.04% 5.48% -135.19%
Net Income Growth		 474.84% 20.42% 22.94% -8.35% 17.06% -54.41% -238.16% 32.03% 285.14% 35.02% -163.58%
EPS Growth		 462.37% 22.56% 24.18% -8.29% 24.52% -53.58% -230.81% 35.14% 270.39% 41.80% -167.51%
Operating Cash Flow Growth		 30.50% 11.36% 17.00% 15.27% -2.82% 15.87% -13.47% 63.39% -14.15% 27.83% -2.88%
Free Cash Flow Firm Growth		 182.64% -310.02% 130.02% 84.87% -26.66% -30.81% -1,726.79% 125.48% -36.84% 61.23% -122.30%
Invested Capital Growth		 -10.30% 93.81% 6.17% -4.50% 3.23% -0.46% 160.24% -15.86% -1.29% -7.89% 0.38%
Revenue Q/Q Growth		 0.97% 3.89% 2.52% 2.16% 5.12% 3.67% 8.08% 2.10% 1.05% 1.91% 2.64%
EBITDA Q/Q Growth		 -4.69% 9.83% 0.27% 4.48% -4.53% 6.79% -4.73% -37.68% 50.65% 4.73% 43.72%
EBIT Q/Q Growth		 -4.35% 11.57% -5.48% 7.61% -19.10% 43.36% -43.67% -137.56% 209.71% 8.02% 13.82%
NOPAT Q/Q Growth		 0.08% 9.01% 34.42% -15.40% -10.94% 16.82% 119.13% -126.50% 501.57% 13.12% 12.91%
Net Income Q/Q Growth		 0.35% 9.35% 31.03% -13.99% -14.04% 33.16% -104.89% -1,099.02% 418.84% 20.93% 3.35%
EPS Q/Q Growth		 -1.51% 9.95% 31.35% -13.71% -13.01% 33.54% -117.32% -867.57% 617.65% 22.18% 5.96%
Operating Cash Flow Q/Q Growth		 -2.66% 11.47% 3.57% 1.72% -14.37% 12.29% -1.08% 14.82% -13.79% 19.85% -2.59%
Free Cash Flow Firm Q/Q Growth		 -7.25% -2.89% 19.66% 4.49% -23.69% 8.19% 14.17% -32.49% 964.67% 108.02% -778.07%
Invested Capital Q/Q Growth		 -3.41% 0.23% 2.70% -0.78% 1.48% 2.10% -1.27% 4.72% 2.70% -6.01% -0.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 92.26% 92.92% 93.19% 93.57% 94.08% 93.70% 85.76% 85.23% 88.64% 89.05% 88.21%
EBITDA Margin		 48.34% 49.12% 44.11% 45.94% 41.48% 27.63% 23.22% 14.89% 31.98% 33.63% 6.17%
Operating Margin		 38.36% 39.76% 32.67% 32.52% 24.63% 16.00% 5.50% -1.79% 15.09% 17.61% -10.08%
EBIT Margin		 38.47% 39.99% 32.06% 32.15% 24.36% 15.86% 5.36% -2.31% 15.32% 17.41% -10.14%
Profit (Net Income) Margin		 24.87% 26.67% 30.14% 23.64% 24.21% 10.10% -10.65% -6.12% 10.82% 13.77% -8.35%
Tax Burden Percent		 75.59% 74.53% 110.59% 84.44% 115.20% 86.74% 292.16% 60.10% 139.24% 119.09% 56.72%
Interest Burden Percent		 85.53% 89.48% 85.01% 87.09% 86.28% 73.40% -68.00% 440.95% 50.72% 66.39% 145.07%
Effective Tax Rate		 24.41% 25.40% -10.82% 15.14% -16.10% 12.18% 0.00% 0.00% -40.25% -19.44% 0.00%
Return on Invested Capital (ROIC)		 20.28% 16.78% 16.38% 14.48% 17.28% 9.16% 1.83% -0.53% 10.31% 11.40% -4.17%
ROIC Less NNEP Spread (ROIC-NNEP)		 6.92% 11.79% 8.72% 5.88% 2.53% -29.81% -14.78% -4.00% 1.41% 3.17% -6.00%
Return on Net Nonoperating Assets (RNNOA)		 1.91% 6.06% 4.88% 1.86% 0.55% -2.11% -10.48% -5.83% 1.85% 2.91% -4.29%
Return on Equity (ROE)		 22.19% 22.83% 21.26% 16.35% 17.84% 7.05% -8.65% -6.36% 12.16% 14.31% -8.47%
Cash Return on Invested Capital (CROIC)		 31.14% -47.08% 10.39% 19.09% 14.10% 9.62% -87.13% 16.69% 11.61% 19.62% -4.55%
Operating Return on Assets (OROA)		 15.28% 14.63% 10.46% 11.77% 9.80% 6.21% 1.76% -0.73% 5.28% 6.05% -3.66%
Return on Assets (ROA)		 9.88% 9.76% 9.83% 8.66% 9.74% 3.95% -3.50% -1.94% 3.73% 4.79% -3.01%
Return on Common Equity (ROCE)		 22.19% 22.83% 21.26% 16.35% 17.84% 7.05% -8.65% -6.36% 12.16% 14.31% -8.47%
Return on Equity Simple (ROE_SIMPLE)		 20.61% 21.14% 17.98% 16.21% 16.82% 6.52% -8.31% -7.26% 11.10% 13.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 384 441 586 522 618 332 119 -46 811 856 -301
NOPAT Margin		 29.00% 29.66% 36.21% 27.59% 28.59% 14.05% 3.85% -1.25% 21.16% 21.04% -7.06%
Net Nonoperating Expense Percent (NNEP)		 13.36% 4.99% 7.66% 8.61% 14.75% 38.97% 16.61% 3.47% 8.90% 8.23% 1.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -0.52% 8.59% 8.39% -3.11%
Cost of Revenue to Revenue		 7.74% 7.08% 6.81% 6.43% 5.92% 6.30% 14.24% 14.77% 11.36% 10.95% 11.79%
SG&A Expenses to Revenue		 33.90% 33.80% 33.62% 36.15% 34.09% 36.14% 46.92% 38.72% 35.03% 34.05% 42.40%
R&D to Revenue		 10.21% 12.50% 17.51% 11.98% 18.95% 24.82% 16.34% 28.27% 22.66% 21.97% 40.55%
Operating Expenses to Revenue		 53.90% 53.16% 60.52% 61.06% 69.46% 77.70% 80.25% 87.02% 73.55% 71.43% 98.29%
Earnings before Interest and Taxes (EBIT)		 510 595 519 608 527 375 166 -85 587 708 -433
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 640 731 714 869 897 653 718 545 1,226 1,369 263
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.41 3.48 2.98 2.71 2.71 2.51 1.98 3.25 2.07 1.82 2.39
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 18.16 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 6.52 4.39 4.99 3.95 3.91 3.89 2.53 2.74 2.02 1.83 2.42
Price to Earnings (P/E)		 26.23 16.46 16.55 16.72 16.14 38.54 0.00 0.00 18.67 13.29 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.81% 6.08% 6.04% 5.98% 6.20% 2.59% 0.00% 0.00% 5.36% 7.52% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.94 2.34 2.46 2.34 2.47 2.53 1.41 1.88 1.51 1.47 1.83
Enterprise Value to Revenue (EV/Rev)		 6.68 5.47 5.59 4.36 4.15 3.87 4.30 4.06 3.09 2.60 3.10
Enterprise Value to EBITDA (EV/EBITDA)		 13.81 11.13 12.68 9.50 10.01 14.02 18.50 27.30 9.65 7.72 50.27
Enterprise Value to EBIT (EV/EBIT)		 17.35 13.67 17.45 13.57 17.04 24.43 80.09 0.00 20.14 14.91 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 23.02 18.43 15.45 15.81 14.52 27.58 111.50 0.00 14.58 12.34 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.63 13.73 13.06 10.33 11.56 10.18 17.07 11.69 10.83 7.57 9.77
Enterprise Value to Free Cash Flow (EV/FCFF)		 14.99 0.00 24.34 12.00 17.80 26.25 0.00 10.28 12.95 7.17 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.74 1.08 0.58 0.58 0.52 0.57 1.53 1.86 1.53 1.49 1.24
Long-Term Debt to Equity		 0.72 1.06 0.57 0.57 0.51 0.51 1.52 1.85 1.37 1.48 1.00
Financial Leverage		 0.28 0.51 0.56 0.32 0.22 0.07 0.71 1.46 1.31 0.92 0.72
Leverage Ratio		 2.25 2.34 2.16 1.89 1.83 1.78 2.47 3.28 3.26 2.99 2.81
Compound Leverage Factor		 1.92 2.09 1.84 1.64 1.58 1.31 -1.68 14.47 1.65 1.98 4.08
Debt to Total Capital		 42.64% 51.95% 36.82% 36.67% 34.06% 36.40% 60.41% 64.97% 60.45% 59.87% 55.37%
Short-Term Debt to Total Capital		 1.35% 0.92% 0.95% 0.77% 0.71% 4.28% 0.31% 0.35% 6.40% 0.30% 10.64%
Long-Term Debt to Total Capital		 41.29% 51.03% 35.87% 35.90% 33.36% 32.12% 60.10% 64.62% 54.05% 59.57% 44.73%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 57.36% 48.05% 63.18% 63.33% 65.94% 63.60% 39.59% 35.03% 39.55% 40.13% 44.63%
Debt to EBITDA		 1.86 2.78 2.21 1.84 1.79 3.21 8.42 10.50 4.66 4.46 20.34
Net Debt to EBITDA		 0.31 2.19 1.37 0.89 0.59 -0.06 7.60 8.89 3.33 2.28 11.07
Long-Term Debt to EBITDA		 1.80 2.73 2.16 1.80 1.76 2.83 8.38 10.45 4.17 4.44 16.43
Debt to NOPAT		 3.09 4.60 2.70 3.06 2.60 6.31 50.76 -124.80 7.04 7.14 -17.79
Net Debt to NOPAT		 0.52 3.63 1.67 1.48 0.86 -0.11 45.79 -105.58 5.04 3.64 -9.68
Long-Term Debt to NOPAT		 3.00 4.52 2.63 3.00 2.55 5.57 50.50 -124.12 6.29 7.10 -14.37
Altman Z-Score		 4.39 2.34 3.07 3.01 3.34 3.12 1.13 1.37 1.42 1.59 1.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.55 2.91 3.29 3.57 4.47 4.34 3.23 2.79 2.24 4.46 1.86
Quick Ratio		 5.29 2.56 2.81 3.15 3.93 3.87 1.43 1.64 1.52 3.57 1.46
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 590 -1,239 372 688 504 349 -5,676 1,446 914 1,473 -329
Operating Cash Flow to CapEx		 1,479.35% 6,115.32% 2,394.08% 0.00% 2,994.68% 5,996.05% 2,816.49% 4,379.18% 4,557.24% 3,666.69% 152.57%
Free Cash Flow to Firm to Interest Expense		 35.08 -1,941.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 31.64 928.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 29.50 913.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.40 0.37 0.33 0.37 0.40 0.39 0.33 0.32 0.35 0.35 0.36
Accounts Receivable Turnover		 6.69 6.70 7.06 7.75 6.98 6.28 6.45 6.02 5.65 5.72 5.52
Inventory Turnover		 4.14 3.94 2.85 2.53 1.94 1.71 0.75 0.61 0.66 0.83 1.12
Fixed Asset Turnover		 18.41 15.41 11.66 10.21 13.03 18.22 16.08 15.09 19.28 23.72 22.87
Accounts Payable Turnover		 4.37 4.77 4.71 3.74 2.96 4.10 6.93 5.66 4.50 4.94 5.03
Days Sales Outstanding (DSO)		 54.56 54.45 51.68 47.10 52.33 58.10 56.61 60.59 64.60 63.80 66.18
Days Inventory Outstanding (DIO)		 88.09 92.65 128.02 144.45 187.68 213.24 483.67 603.29 549.33 441.18 325.41
Days Payable Outstanding (DPO)		 83.54 76.58 77.48 97.55 123.16 89.07 52.69 64.51 81.08 73.96 72.50
Cash Conversion Cycle (CCC)		 59.11 70.52 102.22 93.99 116.85 182.28 487.59 599.37 532.86 431.03 319.09
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,791 3,471 3,685 3,520 3,633 3,617 9,412 7,919 7,817 7,200 7,227
Invested Capital Turnover		 0.70 0.57 0.45 0.52 0.60 0.65 0.48 0.42 0.49 0.54 0.59
Increase / (Decrease) in Invested Capital		 -206 1,680 214 -166 114 -17 5,795 -1,492 -102 -617 27
Enterprise Value (EV)		 8,844 8,134 9,052 8,249 8,975 9,158 13,290 14,874 11,830 10,561 13,246
Market Capitalization		 8,644 6,530 8,072 7,477 8,445 9,196 7,831 10,031 7,744 7,445 10,330
Book Value per Share		 $26.00 $31.35 $45.26 $45.71 $54.99 $65.69 $64.51 $49.01 $59.36 $67.72 $71.07
Tangible Book Value per Share		 ($3.97) ($33.87) ($20.24) ($14.95) ($4.42) $9.09 ($81.58) ($69.90) ($54.55) ($39.34) ($31.93)
Total Capital		 2,787 3,907 4,294 4,354 4,718 5,755 10,015 8,810 9,450 10,202 9,677
Total Debt		 1,188 2,030 1,581 1,596 1,607 2,095 6,050 5,724 5,713 6,109 5,358
Total Long-Term Debt		 1,151 1,994 1,540 1,563 1,574 1,849 6,019 5,693 5,108 6,078 4,328
Net Debt		 200 1,604 980 772 530 -38 5,458 4,843 4,087 3,116 2,916
Capital Expenditures (CapEx)		 36 9.69 29 -28 26 15 28 29 24 38 889
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 80 101 114 97 222 299 1,242 822 877 629 512
Debt-free Net Working Capital (DFNWC)		 1,069 527 715 922 1,299 2,432 1,833 1,704 2,504 3,621 2,953
Net Working Capital (NWC)		 1,031 491 674 889 1,266 2,186 1,802 1,673 1,899 3,590 1,924
Net Nonoperating Expense (NNE)		 55 45 98 75 95 93 449 178 397 296 55
Net Nonoperating Obligations (NNO)		 192 1,594 972 762 522 -43 5,446 4,834 4,080 3,106 2,909
Total Depreciation and Amortization (D&A)		 131 136 195 261 370 278 552 629 639 660 696
Debt-free, Cash-free Net Working Capital to Revenue		 6.03% 6.77% 7.04% 5.14% 10.26% 12.67% 40.13% 22.48% 22.88% 15.45% 11.99%
Debt-free Net Working Capital to Revenue		 80.66% 35.40% 44.17% 48.75% 60.10% 102.90% 59.24% 46.56% 65.30% 89.00% 69.21%
Net Working Capital to Revenue		 77.82% 32.98% 41.66% 46.99% 58.55% 92.48% 58.24% 45.72% 49.52% 88.24% 45.07%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $5.38 $6.56 $8.13 $7.45 $9.22 $4.28 ($5.52) ($3.58) $6.55 $9.06 ($5.84)
Adjusted Weighted Average Basic Shares Outstanding		 61.23M 60.50M 60.02M 59.98M 56.75M 55.71M 59.69M 62.54M 63.29M 61.84M 60.98M
Adjusted Diluted Earnings per Share		 $5.23 $6.41 $7.96 $7.30 $9.09 $4.22 ($5.52) ($3.58) $6.10 $8.65 ($5.84)
Adjusted Weighted Average Diluted Shares Outstanding		 63.04M 61.87M 61.32M 61.22M 57.55M 56.52M 59.69M 62.54M 72.07M 66.01M 60.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.18M 59.74M 59.80M 57.06M 56.13M 56.33M 61.74M 63.33M 62.35M 60.73M 61.56M
Normalized Net Operating Profit after Tax (NOPAT)		 408 441 370 558 373 452 119 48 405 502 -301
Normalized NOPAT Margin		 30.80% 29.66% 22.87% 29.52% 17.24% 19.11% 3.85% 1.30% 10.56% 12.33% -7.06%
Pre Tax Income Margin		 32.91% 35.78% 27.25% 28.00% 21.02% 11.64% -3.65% -10.19% 7.77% 11.56% -14.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 30.31 932.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 22.85 691.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 28.17 917.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 20.71 676.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 18.68% 70.13% 20.25% 117.13% 57.60% 61.41% 0.00% -0.02% 65.03% 55.60% -35.10%

Quarterly Metrics And Ratios for Jazz Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 61,560,350.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 61,560,350.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 4.76
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3.35% 4.10% 1.03% 6.95% 8.52% 7.53% -0.46% 2.14% 6.74% 10.09% 19.06%
EBITDA Growth		 97.45% 340.27% -20.48% 15.30% 27.33% 21.25% -52.27% -241.65% -44.47% 22.71% 378.84%
EBIT Growth		 750.23% 149.59% -50.09% 28.79% 51.75% 39.91% -186.97% -444.18% -77.80% 37.62% 704.46%
NOPAT Growth		 1,365.97% 202.17% -71.23% 19.19% 9.81% 45.29% -184.42% -297.10% 473.59% -9.22% 942.67%
Net Income Growth		 847.25% 139.11% -121.06% 61.40% 46.48% 102.98% -533.06% -526.22% 16.91% 6.45% 416.86%
EPS Growth		 790.32% 136.36% -122.12% 63.82% 59.81% 112.14% -560.87% -571.49% 19.30% 12.46% 391.45%
Operating Cash Flow Growth		 -26.51% -51.07% -16.68% 11.65% 29.80% 138.19% 60.83% -73.18% 19.03% -9.05% -5.03%
Free Cash Flow Firm Growth		 -89.68% -77.78% -74.05% -17.78% 12.41% 206.58% 69.84% -161.46% 765.51% -75.18% -50.95%
Invested Capital Growth		 0.65% -1.29% -3.76% -4.96% 0.64% -7.89% -8.19% -1.21% -5.15% 0.38% 0.63%
Revenue Q/Q Growth		 1.55% 4.09% -10.87% 13.51% 3.04% 3.15% -17.49% 16.47% 7.69% 6.38% -10.77%
EBITDA Q/Q Growth		 5.95% -12.75% -21.70% 59.28% 17.01% -16.92% -69.18% -572.73% 145.87% 83.61% 20.20%
EBIT Q/Q Growth		 10.15% -22.90% -51.07% 209.93% 29.79% -28.91% -130.41% -1,126.61% 108.37% 340.67% 33.57%
NOPAT Q/Q Growth		 24.25% -25.87% -75.40% 425.99% 14.47% -1.91% -114.29% -1,128.07% 433.12% -84.48% 32.70%
Net Income Q/Q Growth		 40.58% -35.87% -115.53% 1,253.15% 27.58% -11.13% -148.42% -676.38% 134.99% -19.08% 44.06%
EPS Q/Q Growth		 40.79% -34.58% -116.43% 1,182.61% 37.35% -13.16% -151.18% -672.37% 134.75% -18.14% 32.63%
Operating Cash Flow Q/Q Growth		 3.51% -45.53% 59.69% 24.00% 20.34% -0.04% 7.83% -79.33% 434.15% -23.62% 12.60%
Free Cash Flow Firm Q/Q Growth		 -73.41% 41.71% 17.98% 84.97% -63.65% 286.50% -34.64% -166.93% 611.90% -88.92% 29.14%
Invested Capital Q/Q Growth		 -3.32% 2.70% -3.00% -1.32% 2.37% -6.01% -3.31% 6.19% -1.70% -0.53% -3.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.49% 89.40% 89.41% 89.27% 89.42% 88.17% 88.35% 88.88% 88.56% 87.18% 87.45%
EBITDA Margin		 34.31% 28.76% 25.27% 35.45% 40.26% 32.43% 12.11% -49.17% 20.94% 36.15% 48.69%
Operating Margin		 17.73% 12.11% 7.34% 19.48% 24.67% 17.53% -6.23% -65.64% 5.11% 21.25% 31.49%
EBIT Margin		 17.59% 13.03% 7.15% 19.53% 24.60% 16.95% -6.25% -65.81% 5.12% 21.19% 31.72%
Profit (Net Income) Margin		 15.10% 9.30% -1.62% 16.46% 20.39% 17.56% -10.31% -68.71% 22.33% 16.98% 27.42%
Tax Burden Percent		 147.53% 153.03% 912.48% 122.22% 107.10% 143.46% 84.27% 97.68% 2,782.65% 97.59% 97.96%
Interest Burden Percent		 58.19% 46.66% -2.48% 68.98% 77.38% 72.22% 195.72% 106.88% 15.68% 82.12% 88.23%
Effective Tax Rate		 -47.40% -53.78% 0.00% -22.22% -7.24% -43.47% 0.00% 0.00% -2,683.17% 2.38% 2.04%
Return on Invested Capital (ROIC)		 13.07% 9.07% 2.55% 12.12% 13.83% 13.63% -2.44% -25.25% 79.18% 12.27% 19.61%
ROIC Less NNEP Spread (ROIC-NNEP)		 10.67% 6.96% 1.11% 10.26% 12.15% 11.33% -4.04% -31.67% 39.48% 10.77% 18.21%
Return on Net Nonoperating Assets (RNNOA)		 15.30% 9.09% 1.33% 11.36% 12.07% 10.40% -3.42% -31.41% 33.00% 7.70% 11.00%
Return on Equity (ROE)		 28.38% 18.16% 3.88% 23.48% 25.90% 24.03% -5.86% -56.65% 112.19% 19.97% 30.61%
Cash Return on Invested Capital (CROIC)		 1.13% 11.61% 13.13% 14.82% 9.27% 19.62% 19.45% -1.52% 0.65% -4.55% -1.01%
Operating Return on Assets (OROA)		 6.18% 4.49% 2.46% 6.75% 8.37% 5.89% -2.22% -24.11% 1.80% 7.64% 12.04%
Return on Assets (ROA)		 5.31% 3.21% -0.56% 5.69% 6.94% 6.11% -3.67% -25.18% 7.86% 6.12% 10.41%
Return on Common Equity (ROCE)		 28.38% 18.16% 3.88% 23.48% 25.90% 24.03% -5.86% -56.65% 112.19% 19.97% 30.61%
Return on Equity Simple (ROE_SIMPLE)		 2.29% 0.00% 8.95% 10.50% 11.10% 0.00% 11.55% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 254 188 46 244 279 274 -39 -480 1,601 248 330
NOPAT Margin		 26.14% 18.62% 5.14% 23.81% 26.45% 25.15% -4.36% -45.95% 142.13% 20.74% 30.85%
Net Nonoperating Expense Percent (NNEP)		 2.40% 2.11% 1.45% 1.86% 1.68% 2.30% 1.60% 6.43% 39.70% 1.50% 1.39%
Return On Investment Capital (ROIC_SIMPLE)		 - 1.99% - - - 2.68% -0.41% -5.30% 17.17% 2.57% 3.34%
Cost of Revenue to Revenue		 10.51% 10.60% 10.59% 10.73% 10.58% 11.83% 11.65% 11.12% 11.44% 12.82% 12.55%
SG&A Expenses to Revenue		 31.71% 39.14% 38.99% 33.06% 30.88% 33.94% 57.25% 34.27% 47.12% 33.91% 33.00%
R&D to Revenue		 24.11% 23.18% 25.82% 21.56% 18.95% 22.10% 20.12% 104.75% 21.37% 17.86% 18.34%
Operating Expenses to Revenue		 71.76% 77.30% 82.07% 69.79% 64.76% 70.64% 94.57% 154.52% 83.45% 65.94% 55.96%
Earnings before Interest and Taxes (EBIT)		 171 132 65 200 260 184 -56 -688 58 254 339
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 334 291 228 363 425 353 109 -514 236 433 521
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.34 2.07 2.05 1.79 1.65 1.82 1.81 1.76 2.02 2.39 2.57
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.15 2.02 1.97 1.72 1.72 1.83 1.85 1.60 1.92 2.42 2.62
Price to Earnings (P/E)		 102.21 18.67 22.92 17.04 14.85 13.29 15.64 0.00 0.00 0.00 395.15
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.98% 5.36% 4.36% 5.87% 6.73% 7.52% 6.40% 0.00% 0.00% 0.00% 0.25%
Enterprise Value to Invested Capital (EV/IC)		 1.62 1.51 1.51 1.40 1.35 1.47 1.48 1.38 1.56 1.83 2.02
Enterprise Value to Revenue (EV/Rev)		 3.24 3.09 2.99 2.67 2.60 2.60 2.54 2.50 2.72 3.10 3.18
Enterprise Value to EBITDA (EV/EBITDA)		 15.12 9.65 9.83 8.60 7.94 7.72 8.27 27.50 61.69 50.27 20.91
Enterprise Value to EBIT (EV/EBIT)		 64.87 20.14 21.95 18.43 15.82 14.91 17.58 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 91.20 14.58 15.97 13.98 13.71 12.34 13.03 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 9.71 10.83 11.05 9.74 8.91 7.57 6.63 7.78 8.13 9.77 10.58
Enterprise Value to Free Cash Flow (EV/FCFF)		 143.35 12.95 11.30 9.19 14.65 7.17 7.31 0.00 233.44 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.64 1.53 1.54 1.52 1.47 1.49 1.29 1.45 1.35 1.24 1.18
Long-Term Debt to Equity		 1.46 1.37 1.38 1.36 1.46 1.48 1.28 1.17 1.09 1.00 0.95
Financial Leverage		 1.43 1.31 1.20 1.11 0.99 0.92 0.85 0.99 0.84 0.72 0.60
Leverage Ratio		 3.46 3.26 3.18 3.10 3.06 2.99 2.90 2.99 2.90 2.81 2.69
Compound Leverage Factor		 2.02 1.52 -0.08 2.14 2.37 2.16 5.68 3.19 0.46 2.31 2.37
Debt to Total Capital		 62.09% 60.45% 60.71% 60.27% 59.44% 59.87% 56.25% 59.14% 57.52% 55.37% 54.16%
Short-Term Debt to Total Capital		 6.57% 6.40% 6.44% 6.40% 0.30% 0.30% 0.32% 11.34% 11.04% 10.64% 10.42%
Long-Term Debt to Total Capital		 55.52% 54.05% 54.27% 53.87% 59.14% 59.57% 55.92% 47.80% 46.48% 44.73% 43.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 37.91% 39.55% 39.30% 39.73% 40.56% 40.13% 43.75% 40.86% 42.48% 44.63% 45.84%
Debt to EBITDA		 7.02 4.66 4.89 4.70 4.68 4.46 4.30 14.41 29.24 20.34 7.93
Net Debt to EBITDA		 5.07 3.33 3.33 3.07 2.67 2.28 2.24 9.92 18.08 11.07 3.67
Long-Term Debt to EBITDA		 6.28 4.17 4.37 4.20 4.65 4.44 4.27 11.65 23.63 16.43 6.40
Debt to NOPAT		 42.37 7.04 7.95 7.63 8.08 7.14 6.77 -26.31 -15.50 -17.79 -202.69
Net Debt to NOPAT		 30.61 5.04 5.42 4.98 4.62 3.64 3.53 -18.12 -9.59 -9.68 -93.89
Long-Term Debt to NOPAT		 37.89 6.29 7.10 6.82 8.04 7.10 6.73 -21.26 -12.53 -14.37 -163.68
Altman Z-Score		 1.31 1.29 1.27 1.27 1.34 1.44 1.38 0.87 1.24 1.56 1.77
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.06 2.24 2.27 2.37 4.26 4.46 3.38 1.62 1.65 1.86 2.04
Quick Ratio		 1.41 1.52 1.62 1.72 3.24 3.57 2.64 1.15 1.24 1.46 1.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 205 291 343 634 230 891 582 -390 1,995 221 286
Operating Cash Flow to CapEx		 7,145.73% 1,656.49% 3,870.64% 4,672.85% 3,696.21% 2,999.77% 3,096.20% 10.20% 3,127.62% 2,167.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.35 0.35 0.34 0.35 0.34 0.35 0.36 0.37 0.35 0.36 0.38
Accounts Receivable Turnover		 6.17 5.65 5.78 5.98 5.91 5.72 5.98 5.79 5.59 5.52 5.96
Inventory Turnover		 0.74 0.66 0.64 0.69 0.74 0.83 0.85 0.88 0.94 1.12 1.15
Fixed Asset Turnover		 17.29 19.28 19.52 19.62 20.02 23.72 23.56 23.07 22.76 22.87 23.24
Accounts Payable Turnover		 4.67 4.50 3.90 4.24 4.35 4.94 5.14 4.95 4.03 5.03 5.44
Days Sales Outstanding (DSO)		 59.11 64.60 63.20 61.07 61.77 63.80 61.06 63.06 65.31 66.18 61.23
Days Inventory Outstanding (DIO)		 493.31 549.33 567.83 527.88 495.19 441.18 429.36 414.51 389.96 325.41 318.65
Days Payable Outstanding (DPO)		 78.09 81.08 93.62 86.03 84.00 73.96 70.98 73.78 90.64 72.50 67.11
Cash Conversion Cycle (CCC)		 474.33 532.86 537.42 502.93 472.96 431.03 419.44 403.78 364.63 319.09 312.77
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 7,612 7,817 7,583 7,483 7,660 7,200 6,961 7,392 7,266 7,227 7,006
Invested Capital Turnover		 0.50 0.49 0.50 0.51 0.52 0.54 0.56 0.55 0.56 0.59 0.64
Increase / (Decrease) in Invested Capital		 49 -102 -296 -390 49 -617 -621 -91 -394 27 44
Enterprise Value (EV)		 12,302 11,830 11,473 10,454 10,374 10,561 10,335 10,235 11,310 13,246 14,118
Market Capitalization		 8,172 7,744 7,581 6,728 6,880 7,445 7,540 6,540 7,995 10,330 11,638
Book Value per Share		 $55.27 $59.36 $59.11 $59.69 $67.54 $67.72 $68.74 $60.14 $65.27 $71.07 $73.62
Tangible Book Value per Share		 ($57.56) ($54.55) ($52.43) ($48.43) ($44.98) ($39.34) ($37.93) ($47.16) ($40.13) ($31.93) ($23.98)
Total Capital		 9,205 9,450 9,407 9,469 10,283 10,202 9,542 9,070 9,320 9,677 9,887
Total Debt		 5,715 5,713 5,710 5,707 6,112 6,109 5,367 5,364 5,361 5,358 5,355
Total Long-Term Debt		 5,111 5,108 5,105 5,101 6,081 6,078 5,336 4,336 4,332 4,328 4,324
Net Debt		 4,130 4,087 3,892 3,726 3,494 3,116 2,796 3,694 3,315 2,916 2,480
Capital Expenditures (CapEx)		 4.30 10 6.90 7.09 11 13 14 871 15 17 -103
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 691 877 765 751 773 629 364 638 465 512 493
Debt-free Net Working Capital (DFNWC)		 2,277 2,504 2,583 2,731 3,391 3,621 2,936 2,308 2,511 2,953 3,367
Net Working Capital (NWC)		 1,672 1,899 1,978 2,126 3,360 3,590 2,905 1,279 1,482 1,924 2,337
Net Nonoperating Expense (NNE)		 107 94 61 75 64 83 53 238 1,349 45 37
Net Nonoperating Obligations (NNO)		 4,122 4,080 3,886 3,720 3,489 3,106 2,787 3,686 3,307 2,909 2,473
Total Depreciation and Amortization (D&A)		 163 159 163 163 165 168 165 174 178 179 181
Debt-free, Cash-free Net Working Capital to Revenue		 18.22% 22.88% 19.90% 19.20% 19.37% 15.45% 8.96% 15.61% 11.18% 11.99% 11.10%
Debt-free Net Working Capital to Revenue		 60.01% 65.30% 67.21% 69.86% 84.94% 89.00% 72.23% 56.47% 60.39% 69.21% 75.86%
Net Working Capital to Revenue		 44.08% 49.52% 51.46% 54.37% 84.16% 88.24% 71.47% 31.30% 35.64% 45.07% 52.64%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.33 $1.50 ($0.23) $2.68 $3.50 $3.11 ($1.52) ($11.74) $4.14 $3.28 $4.73
Adjusted Weighted Average Basic Shares Outstanding		 63.11M 63.29M 62.54M 62.88M 61.41M 61.84M 60.98M 61.19M 60.70M 60.98M 61.90M
Adjusted Diluted Earnings per Share		 $2.14 $1.40 ($0.23) $2.49 $3.42 $2.97 ($1.52) ($11.74) $4.08 $3.34 $4.43
Adjusted Weighted Average Diluted Shares Outstanding		 71.29M 72.07M 62.54M 69.63M 63.17M 66.01M 60.98M 61.19M 61.61M 60.98M 66.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 62.96M 62.35M 63.04M 61.75M 60.45M 60.73M 61.63M 60.66M 60.77M 61.56M 62.74M
Normalized Net Operating Profit after Tax (NOPAT)		 121 86 46 140 182 134 -39 -480 40 248 209
Normalized NOPAT Margin		 12.41% 8.47% 5.14% 13.64% 17.27% 12.27% -4.36% -45.95% 3.57% 20.74% 19.59%
Pre Tax Income Margin		 10.24% 6.08% -0.18% 13.47% 19.03% 12.24% -12.23% -70.34% 0.80% 17.40% 27.99%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 212.58% 65.03% 0.00% 84.98% 88.79% 55.60% 0.00% -67.93% -33.93% -35.10% 0.00%

Financials Breakdown Chart

Key Financial Trends

Jazz Pharmaceuticals (JAZZ) has shown a mix of steady margin performance with notable swings in net income and cash flow driven by high research & development spending and occasional large investing activities. Below is a concise, data-driven view of the last four years, focused on trends in the income statement, cash flow, and balance sheet, tailored for retail investors.

  • Revenue growth in late 2025: Q4 2025 revenue reached about $1.20B, up from roughly $1.09B in Q4 2024, indicating overall topline advancement into the latest year.
  • High but stable gross margins: Gross margin has remained in the high-80s across the period (example: Q4 2025 gross profit of $1.044B on $1.198B revenue ≈ 87%). This suggests pricing and product mix have supported robust profitability after cost of revenue.
  • Net income posted in recent quarters: Net income for Q3 2025 and Q4 2025 was positive ($251.4M and $203.5M, respectively), signaling profitability despite ongoing R&D investments.
  • Strong operating cash flow in recent quarters: Net cash from continuing operating activities was robust in recent periods (e.g., Q4 2025: $362.5M; Q3 2025: $474.6M; Q1 2025: $429.8M), indicating solid cash generation from core operations.
  • Liquidity remains solid and growing: Cash & equivalents were about $1.3B in mid-2025, with a positive net change in cash in Q4 2025 (+$65.8M), suggesting liquidity remained healthy through the latest quarter.
  • R&D spending remains a key cost driver: R&D expense is consistently high (Q4 2025: $213.9M; Q4 2024 and other quarters show similar levels), which supports future product potential but depresses near-term operating income in some quarters (e.g., Q2 2025 ROIC/operating income weakness due to higher RD spend).
  • Investing activity shows sizable cash outflows: Net cash from continuing investing activities has been negative in several quarters due to acquisitions and investments (examples: Q2 2025 around -$641.0M; Q3 2025 around -$327.8M; Q4 2025 around -$372.2M), reflecting ongoing expansion or portfolio refinement.
  • Debt levels remain meaningful but stable: Long-term debt sits in the mid-to-high $4B range (e.g., around $4.3B in mid-2025); total liabilities are about $7–8B with equity around $3–4B, indicating a substantial but manageable leverage profile that warrants watching for interest costs and debt maturities.
  • Quarterly earnings volatility remains a risk: Several quarters show meaningful net losses (e.g., Q2 2025 net income continuing operations around -$718.5M; Q1 2025 around -$92.5M), highlighting earnings sensitivity to RD timing and tax effects.
  • Interest income is a recurring drag on profits: Interest & investment income has often been negative (example: Q4 2025 ≈ -$45.4M; Q3 2025 ≈ -$48.6M), compressing net income regardless of operating results.
05/14/26 02:32 PM ETAI Generated. May Contain Errors.

Jazz Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Jazz Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Jazz Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$356.15 million in 2025, falling from $329.53 million in 2015. The previous period was $560.12 million in 2024. View Jazz Pharmaceuticals' forecast to see where analysts expect Jazz Pharmaceuticals to go next.

Jazz Pharmaceuticals' total operating income in 2025 was -$430.24 million, based on the following breakdown:
  • Total Gross Profit: $3.76 billion
  • Total Operating Expenses: $4.19 billion

Over the last 10 years, Jazz Pharmaceuticals' total revenue changed from $1.32 billion in 2015 to $4.27 billion in 2025, a change of 222.1%.

Jazz Pharmaceuticals' total liabilities were at $7.34 billion at the end of 2025, a 7.3% decrease from 2024, and a 323.3% increase since 2015.

In the past 10 years, Jazz Pharmaceuticals' cash and equivalents has ranged from $309.62 million in 2018 to $2.41 billion in 2024, and is currently $1.39 billion as of their latest financial filing in 2025.

Over the last 10 years, Jazz Pharmaceuticals' book value per share changed from 26.00 in 2015 to 71.07 in 2025, a change of 173.4%.


Related Companies

Financial statements for NASDAQ:JAZZ last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
J.P. Morgan is betting on this coin
For the first time in history, autonomous AI programs can hold, send, and receive funds — completely without h...
Crypto 101 Media | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...
Equiscreen | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel